Extended data 4: Protection against secondary S. aureus infection is independent of IL1R1-Aim2 activation.

(A-B) (A) Dermonecrosis and (B) bacterial load in WT C57BL/6 and Il1r1^−/− mice treated with PBS or infected with WT LAC on day 0 and challenged at the same site on day 28 with WT LAC; black asterisks denote statistical differences in lesion size with respect to uninfected mice, purple asterisks show statistical difference between WT C57BL/6 and Il1r1^−/−-infected mice and green asterisks show statistical differences between WT C57BL/6 and Il1r1^−/−-naïve mice upon secondary challenge, n = 2 (C57BL/6 or Il1r1^−/− PBS PBS), n = 5 (C57BL/6 PBS WT or C57BL/6 WT WT), n = 4 (Il1r1^−/− PBS WT) or n = 6 (Il1r1^−/− WT WT) independent animals. (C-D) (C) Dermonecrosis and (D) bacterial load in the skin of WT C57BL/6 and Aim2^−/− mice 5 days post infection with WT LAC, ns: not significant, n = 3 or 4 independent animals (day 1) or n = 10 independent animals (day 5). (E) Intracellular mean fluorescence intensity (MFI) of Aim2 measured by flow cytometry in keratinocytes infected with WT LAC or transfected with poly dA:dT for 24 h, n = 1 representative experiment from 3 independent experiments. (F) Expression of Aim2 in HEKn cells infected with WT LAC or transfected with poly dA:dT for 24 h, compared to uninfected cells (PBS) by qRT-PCR, n = 1 representative experiment from 3 independent experiments, For (A-F), data represent mean ± SEM. Statistical analysis was performed by one-way (B) or two-way ANOVA (A, C and D), ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05, ns; p = 0.9999 (C, day 1), 0.9051 (C, day 2), 0.6533 (C, day 3), 0.9820 (C, day 4), 0.9899 (C, day 5) and p = 0.0892 (D, day 1) and 0.4037 (D, day 5).